Gordon Mills, M.D., Ph.D
Stories this photo appears in:
Combination Therapy Targets Genetic Mutation Found in Many Cancers
In vitro/in vivo study shows potential for clinical investigation of PARP and MEK inhibitors for treatment of RAS-mutant cancers
A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused by a mutation of the RAS gene found in many cancers. The pre-clinical study combined therapies targeting the inhibitors polyADP ribose polymerase (PARP) and mitogen-activated protein kinase (MEK). The findings were published this week in Science Translational Medicine.
